Relações entre o uso de anfetaminas e sintomas psicóticos: uma revisão sistemática
DOI:
https://doi.org/10.11606/issn.1679-9836.v101i2e-171974Palavras-chave:
Metanfetamina, Transtornos psicóticos, PsiquiatriaResumo
Anfetaminas são substâncias com ações no sistema nervoso central e periférico com potencial de causar dano intenso e de desencadear sintomas psicóticos (delírios, alucinações). Esta revisão procurou identificar trabalhos com informações essenciais para a compreensão das relações entre o uso dessas substâncias por indivíduos e o desenvolvimento de quadros psicóticos, tanto transitórios, ocorridos apenas durante o uso, quanto persistentes durante e após o período de abstinência, ou evoluindo para transtornos primários, como a esquizofrenia. Através de busca em dois bancos de dados foi possível selecionar as referências que supriram os objetivos. Diversas pesquisas buscaram desvendar os mecanismos de ação dessas drogas, e as bases neurológicas, bioquímicas, fisiológicas e moleculares dos transtornos psicóticos, procurando evidências das ligações entre as três situações citadas anteriormente, e similaridades significativas entre os quadros foram identificadas, incluindo em exames de neuroimagem e análises de quadros clínicos, além de comprovações estatísticas. Contudo, futuros estudos são necessários para esclarecer alguns aspectos desse tema e melhorar classificação etiológica, clínica e diagnóstica, além do manejo desses pacientes.
Downloads
Referências
Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55-70. https://doi.org/10.1016/S0140-6736(11)61138-0.
Mullen JM, Richards JR, Crawford AT. Amphetamine related psychiatric disorders. StatPearls Publishing; 2020 [cited 2020 March 17]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482368/.
Bramness JG, Gundersen ØH, Guterstam J, Rognli EB, Konstenius M, Løberg EM, Medhus S, Tanum L, Franck J. Amphetamine-induced psychosis: a separate diagnostic entity or primary psychosis triggered in the vulnerable. BMC Psychiatry. 2012;12:221. https://doi.org/10.1186/1471-244X-12-221.
Henning A, Kurtom M, Espiridion ED. A case study of acute stimulant-induced psychosis. Cureus. 2019;11(2):e4126. https://doi.org/10.7759/cureus.4126.
Chiang M, Lombardi D, Du J, Makrum U, Sitthichai R, Harrington A, Shukair N, Zhao M, Fan X. Methamphetamine-associated psychosis: clinical presentation, biological basis, and treatment options. Hum Psychopharmacol. 2019;34(5):e2710. https://doi.org/10.1002/hup.2710.
United Nations. The United Nations Office on Drugs and Crime (UNODC). World Drug Report 2019. United Nations Publications; 2019. Available from: https://wdr.unodc.org/wdr2019/
Lamyai W, Pono K, Indrakamhaeng D, et al. Risks of psychosis in methamphetamine users: cross-sectional study in Thailand. BMJ Open. 2019;9(10):e032711. https://doi.org/10.1136/bmjopen-2019-032711.
Lecomte T, Dumais A, Dugré JR, Potvin S. The prevalence of substance-induced psychotic disorder in methamphetamine misusers: a meta-analysis. Psychiatry Res. 2018;268:189-92. https://doi.org/10.1016/j.psychres.2018.05.033.
Vallersnes OM, Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I; Euro-DEN Research Group, Dargan PI. Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry. 2016;16:293. doi: https://doi.org/10.1186/s12888-016-1002-7. Erratum in: BMC Psychiatry. 2016;16(1):405.
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-5®). Washington, DC: American Psychiatric Pub; 2013.
Hajebi A, Amini H, Kashani L, Sharifi V. Twelve-month course and outcome of methamphetamine-induced psychosis compared with first episode primary psychotic disorders. Early Interv Psychiatry. 2018;12(5):928-34. https://doi.org/10.1111/eip.12404.
Hides L, Dawe S, McKetin R, Kavanagh DJ, Young RM, Teesson M, Saunders JB. Primary and substance-induced psychotic disorders in methamphetamine users. Psychiatry Res. 2015;226(1):91-6. https://doi.org/10.1016/j.psychres.2014.11.077.
McKetin R, Voce A, Burns R, Ali R, Lubman DI, Baker AL, Castle DJ. Latent psychotic symptom profiles amongst people who use methamphetamine: what do they tell us about existing diagnostic categories. Front Psychiatry. 2018;9:article578. https://doi.org/10.3389/fpsyt.2018.00578.
Chivaurah BM, Lienert D, Coates D. Amphetamine-type-substance-related presentations to the emergency department mental health team of a local health district in Australia. Australas Psychiatry. 2019;27(4):369-73. https://doi.org/10.1177/1039856219848836.
Medhus S, Rognli EB, Gossop M, Holm B, Mørland J, Bramness JG. Amphetamine-induced psychosis: transition to schizophrenia and mortality in a small prospective sample. Am J Addict. 2015;14(7):586-9. https://doi.org/10.1111/ajad.12274.
Rognli EB, Bramness JG, Skurtveit S, Bukten A. Substance use and sociodemographic background as risk factors for lifetime psychotic experiences in a non-clinical sample. J Subst Abuse Treat. 2017;74:42-7. https://doi.org/10.1016/j.jsat.2016.12.007.
Jo HS, Wang SM, Kim JJ. Recurrent psychosis after phentermine administration in a young female: a case report. Clin Psychopharmacol Neurosci. 2019;17(1):130-3. https://doi.org/10.9758/cpn.2019.17.1.130.
Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019;380(12):1128-38. https://doi.org/10.1056/NEJMoa1813751.
Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G, Rawson R, London ED. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction. 2010;105(10):1809-18. https://doi.org/10.1111/j.1360-0443.2010.03066.x.
Murray RM, Paparelli A, Morrison PD, Marconi A, Di Forti M. What can we learn about schizophrenia from studying the human model, drug-induced psychosis? Am J Med Genet B Neuropsychiatr Genet. 2013;162(7):661-70. https://doi.org/10.1002/ajmg.b.32177.
Castle DJ, Buckley P. Schizophrenia. 2nd ed. Oxford: Oxford University Press; 2015.
Maia TV, Frank MJ. An integrative perspective on the role of dopamine in schizophrenia. Biol Psychiatry. 2017;81(1):52-66. https://doi.org/10.1016/j.biopsych.2016.05.021.
Voce A, Burns R, Castle D, Calabria B, McKetin R. Is there a discrete negative symptom syndrome in people who use methamphetamine? Compr Psychiatry. 2019;93:27-32. https://doi.org/10.1016/j.comppsych.2019.06.002.
Hsieh JH, Stein DJ, Howells FM. The neurobiology of methamphetamine induced psychosis. Front Hum Neurosci. 2014;8:537. https://doi.org/10.3389/fnhum.2014.00537.
Goodman LS, Brunton LL, Chabner BA, Knollmann BC. Goodman and Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011.
Niemi-Pynttӓri JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013;74(1):e94-99. https://doi.org/10.4088/JCP.12m07822.
Thomsen KR, Thylstrup B, Pedersen MM, Pedersen MU, Simonsen E, Hesse M. Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders. Schizophr Res. 2018;195:495-500. https://doi.org/10.1016/j.schres.2017.09.026.
Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, Boileau I, Kish SJ. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry. 2012;169(4):389-96. https://doi.org/10.1176/appi.ajp.2011.10070937.
McInnis P, Lee A. Methamphetamine use in an early psychosis service: a cross-sectional retrospective cohort study. Australas Psychiatry. 2019;27(4):383-7. https://doi.org/10.1177/1039856219859811.
McKetin R, Gardner J, Baker AL, Dawe S, Ali R, Voce A, Leach LS, Lubman DI. Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users. Psychiatry Res. 2016;238:166-71. https://doi.org/10.1016/j.psychres.2016.02.038.
Bousman CA, McKetin R, Burns R, Woods SP, Morgan EE, Atkinson JH, Everall IP, Grant I; Translational Methamphetamine AIDS Research Center (TMARC) Group. Typologies of positive psychotic symptoms in methamphetamine dependence. Am J Addict. 2015;24(2):94-7. https://doi.org/10.1111/ajad.12160.
Shin EJ, Dang DK, Tran TV, Tran HQ, Jeong JH, Nah SY, Jang CG, Yamada K, Nabeshima T, Kim HC. Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors. Arch Pharm Res. 2017;40(4):403-28. https://doi.org/10.1007/s12272-017-0897-y.
Sulzer D. How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron. 2011;69(4):628-49. https://doi.org/10.1016/j.neuron.2011.02.010.
Baig AM. Dark side of amphetamine and analogues: pharmacology, syndromic manifestation, and management of amphetamine addiction. ACS Chem Neurosci. 2018;9(10):2299-303. https://doi.org/10.1021/acschemneuro.8b00137.
Jiao D, Liu Y, Li X, Liu J, Zhao M. The role of the GABA system in amphetamine-type stimulant use disorders. Front Cell Neurosci. 2015;9:162. https://doi.org/10.3389/fncel.2015.00162.
Gross NB, Duncker PC, Marshall JF. Striatal dopamine D1 and D2 receptors: widespread influences on methamphetamine-induced dopamine and serotonin neurotoxicity. Synapse. 2011;65(11):1144-55. https://doi.org/10.1002/syn.20952.
Reichel CM, Ramsey LA, Schwendt M, McGinty JF, See RE. Methamphetamine-induced changes in the object recognition memory circuit. Neuropharmacology. 2012;62(2):1119-26. https://doi.org/10.1016/j.neuropharm.2011.11.033.
Bosch PJ, Peng L, Kivell BM. Proteomics analysis of dorsal striatum reveals changes in synaptosomal proteins following methamphetamine self-administration in rats. PLoS One. 2015;10(10):e0139829.. https://doi.org/10.1371/journal.pone.0139829.
Iamjan S, Thanoi S, Watiktinkorn P, Reynolds GP, Nudmamud-Thanoi S. Genetic variation of GRIA3 gene is associated with vulnerability to methamphetamine dependence and its associated psychosis. J Psychopharmacol. 2018;32(3):309-15. https://doi.org/10.1177/0269881117750153.
Chanasong R, Thanoi S, Watiktinkorn P, Reynolds GP, Nudmamud-Thanoi S. Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population. Neurosci Lett. 2013;551:58-61. https://doi.org/10.1016/j.neulet.2013.07.017.
Vuletic D, Dupont P, Robertson F, Warwick J, Zeevaart JR, Stein DJ. Methamphetamine dependence with and without psychotic symptoms: a multi-modal brain imaging study. Neuroimage Clin. 2018;20:1157-62. https://doi.org/10.1016/j.nicl.2018.10.023.
Yu S, Zhu L, Shen Q, Bai X, Di X. Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology. Behav Neurol. 2015;2015:103969. https://doi.org/10.1155/2015/103969.
Breen MS, Uhlmann A, Nday CM, Glatt SJ, Mitt M, Metsalpu A, Stein DJ, Illing N. Candidate gene networks and blood biomarkers of methamphetamine-associated psychosis: an integrative RNA-sequencing report. Transl Psychiatry. 2016;6(5):e802. https://doi.org/10.1038/tp.2016.67.
Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, Barr AM. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013;129(3):167-79, https://doi.org/10.1016/j.drugalcdep.2012.11.016.
Uhlmann A, Fouche JP, Koen N, Meintjes EM, Wilson D, Stein DJ. Fronto-temporal alterations and affect regulation in methamphetamine dependence with and without a history of psychosis. Psychiatry Res Neuroimaging. 2016;248:30-38. https://doi.org/10.1016/j.psychresns.2016.01.010.
Uhlmann A, Fouche JP, Lederer K, Meintjes EM, Wilson D, Stein DJ. White matter microstructure and impulsivity in methamphetamine dependence with and without a history of psychosis. Hum Brain Mapp. 2016;37(6):2055-67. https://doi.org/10.1002/hbm.23159.
Ipser JC, Uhlmann A, Taylor P, Harvey BH, Wilson D, Stein DJ. Distinct intrinsic functional brain network abnormalities in methamphetamine-dependent patients with and without a history of psychosis. Addict Biol. 2018;23(1):347-58. https://doi.org/10.1111/adb.12478.
Zhang S, Hu Q, Tang T, Liu C, Li C, Zang YY, Cai WX. Changes in gray matter density, regional homogeneity, and functional connectivity in methamphetamine-associated psychosis: a resting-state functional resonance imaging (fMRI) study. Med Sci Monit. 2018;24:4020-30. https://doi.org/10.12659/MSM.905354.
McKetin R, Baker AL, Dawe S, Voce A, Lubman DI. Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders. Psychiatry Res. 2017;251:349-54. https://doi.org/10.1016/j.psychres.2017.02.028.
Medhus S, Mordal J, Holm B, Mørland J, Bramness JG. A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. Psychiatry Res. 2013;206(1):17-21. https://doi.org/10.1016/j.psychres.2012.09.023.
Ma J, Li XD, Wang TY, Li SX, Meng SQ, Blow FC, Ilgen M, Degenhardt L, Lappin J, Wu P, Shi J, Bao YP, Lu L. Relationship between the duration of methamphetamine use and psychotic symptoms: a two-year prospective cohort study. Drug Alcohol Depend. 2018;187:363-9. https://doi.org/10.1016/j.drugalcdep.2018.03.023.
Akiyama K, Saito A, Shimoda K. Chronic methamphetamine psychosis after long-term abstinence in japanese incarcerated patients. Am J Addict. 2011;20(3):240-9. https://doi.org/10.1111/j.1521-0391.2011.00124.
Voce A, Calabria B, Burns R, Castle D, McKetin R. A systematic review of the symptom profile and course of methamphetamine-associated psychosis. Subst Use Misuse. 2019;54(4):549-59. https://doi.org/10.1080/10826084.2018.1521430.
Wang LJ, Lin SK, Chen YC, Huang MC, Chen TT, Ree SC, Chen CK. Differences in clinical features of methamphetamine users with persistent psychosis and patients with schizophrenia. Psychopathology. 2016;49(2):108-15. https://doi.org/10.1159/000445065.
Farnia V, Shakeri J, Tatari F, Juibari TA, Yazdchi K, Bajoghli H, Brand S, Abdoli N, Aghaei A. Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis. Am J Drug Alcohol Abuse. 2014;40(1):10-15. https://doi.org/10.3109/00952990.2013.861843.
Verachai V, Rukngan W, Chawanakrasaesin K, Nilaban S, Suwanmajo S, Thanateerabunjong R, Kaewkungwal J, Kalayasiri R. Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine. Psychopharmacology (Berl). 2014;231(16):3099-3108. https://doi.org/10.1007/s00213-014-3485-6.
Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ. Treatment of toxicity from amphetamines, related derivatives and analogues: a systematic review. Drug Alcohol Depend. 2015;150:1-13. https://doi.org/10.1016/j.drugalcdep.2015.01.040.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Vinícius Henrique Mesquita, Raquel Lautenschlager Santana Proença, Raquel Henriques Rambaldi
Este trabalho está licenciado sob uma licença Creative Commons Attribution-ShareAlike 4.0 International License.
